Loading company…
SymBio Pharmaceuticals Limited, based in Tokyo, develops and commercializes biopharmaceuticals, mainly for oncology.
Founded in 2005 and headquartered in Tokyo, Japan, SymBio Pharmaceuticals Limited develops and commercializes biopharmaceuticals. Its flagship TREAKISYM (bendamustine hydrochloride) is used for relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Heights Capital Management invested JPY 662 million in a PIPE funding round, with the most recent deal on May 16, 2022, and the company has engaged in 10 notable deals.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in